This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murdoch, D. R.
Right arrow Articles by Reller, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murdoch, D. R.
Right arrow Articles by Reller, L. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3623-3624, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3623-3624.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antimicrobial Susceptibilities of Group B Streptococci Isolated from Patients with Invasive Disease: 10-Year Perspective

David R. Murdoch* and L. Barth Reller

Clinical Microbiology Laboratory, Duke University Medical Center, Durham, North Carolina 27710

Received 1 June 2001/Returned for modification 3 July 2001/Accepted 5 September 2001

Antimicrobial susceptibility testing of 192 group B streptococcal isolates from patients with invasive disease demonstrated that 31 (16%) were resistant to erythromycin and 17 (9%) were resistant to clindamycin. One isolate demonstrated high-level resistance to streptomycin, but none was highly resistant to gentamicin. Erythromycin and clindamycin are no longer reliable empirical alternatives to penicillin for the treatment and prevention of group B streptococcal infections.


* Corresponding author. Present address: Microbiology Unit, Canterbury Health Laboratories, P.O. Box 151, Christchurch, New Zealand. Phone: 64 3 364 0347. Fax: 64 3 364 0238. E-mail: david.murdoch{at}cdhb.govt.nz.


Antimicrobial Agents and Chemotherapy, December 2001, p. 3623-3624, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3623-3624.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Nagano, N., Nagano, Y., Kimura, K., Tamai, K., Yanagisawa, H., Arakawa, Y. (2008). Genetic Heterogeneity in pbp Genes among Clinically Isolated Group B Streptococci with Reduced Penicillin Susceptibility. Antimicrob. Agents Chemother. 52: 4258-4267 [Abstract] [Full Text]  
  • Richter, S. S., Howard, W. J., Weinstein, M. P., Bruckner, D. A., Hindler, J. F., Saubolle, M., Doern, G. V. (2007). Multicenter Evaluation of the BD Phoenix Automated Microbiology System for Antimicrobial Susceptibility Testing of Streptococcus Species. J. Clin. Microbiol. 45: 2863-2871 [Abstract] [Full Text]  
  • Gygax, S. E., Schuyler, J. A., Kimmel, L. E., Trama, J. P., Mordechai, E., Adelson, M. E. (2006). Erythromycin and clindamycin resistance in group B streptococcal clinical isolates.. Antimicrob. Agents Chemother. 50: 1875-1877 [Abstract] [Full Text]  
  • Zeng, X., Kong, F., Wang, H., Darbar, A., Gilbert, G. L. (2006). Simultaneous Detection of Nine Antibiotic Resistance-Related Genes in Streptococcus agalactiae Using Multiplex PCR and Reverse Line Blot Hybridization Assay. Antimicrob. Agents Chemother. 50: 204-209 [Abstract] [Full Text]  
  • Wehbeh, W., Rojas-Diaz, R., Li, X., Mariano, N., Grenner, L., Segal-Maurer, S., Tommasulo, B., Drlica, K., Urban, C., Rahal, J. J. (2005). Fluoroquinolone-Resistant Streptococcus agalactiae: Epidemiology and Mechanism of Resistance. Antimicrob. Agents Chemother. 49: 2495-2497 [Abstract] [Full Text]  
  • Desjardins, M., Delgaty, K. L., Ramotar, K., Seetaram, C., Toye, B. (2004). Prevalence and Mechanisms of Erythromycin Resistance in Group A and Group B Streptococcus: Implications for Reporting Susceptibility Results. J. Clin. Microbiol. 42: 5620-5623 [Abstract] [Full Text]  
  • Tang, P., Ng, P., Lum, M., Skulnick, M., Small, G. W., Low, D. E., Sarabia, A., Mazzulli, T., Wong, K., Simor, A. E., Willey, B. M. (2004). Use of the Vitek-1 and Vitek-2 Systems for Detection of Constitutive and Inducible Macrolide Resistance in Group B Streptococci. J. Clin. Microbiol. 42: 2282-2284 [Abstract] [Full Text]  
  • Acikgoz, Z. C., Almayanlar, E., Gamberzade, S., Gocer, S. (2004). Macrolide Resistance Determinants of Invasive and Noninvasive Group B Streptococci in a Turkish Hospital. Antimicrob. Agents Chemother. 48: 1410-1412 [Abstract] [Full Text]  
  • Heelan, J. S., Hasenbein, M. E., McAdam, A. J. (2004). Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin. J. Clin. Microbiol. 42: 1263-1264 [Abstract] [Full Text]  
  • Kawamura, Y., Fujiwara, H., Mishima, N., Tanaka, Y., Tanimoto, A., Ikawa, S., Itoh, Y., Ezaki, T. (2003). First Streptococcus agalactiae Isolates Highly Resistant to Quinolones, with Point Mutations in gyrA and parC. Antimicrob. Agents Chemother. 47: 3605-3609 [Abstract] [Full Text]  
  • Lopardo, H. A., Vidal, P., Jeric, P., Centron, D., Paganini, H., Facklam, R. R., Elliott, J. (2003). Six-Month Multicenter Study on Invasive Infections Due to Group B Streptococci in Argentina. J. Clin. Microbiol. 41: 4688-4694 [Abstract] [Full Text]  
  • Werno, A. M., Anderson, T. P., Murdoch, D. R. (2003). Antimicrobial Susceptibilities of Group B Streptococci in New Zealand. Antimicrob. Agents Chemother. 47: 2710-2711 [Full Text]  
  • Baker, C J, Edwards, M S (2003). Group B streptococcal conjugate vaccines. Arch. Dis. Child. 88: 375-378 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Rodriguez-Avial, I., Sanchez, B. A., Agreda, M. C., Picazo, J. J. (2003). Erythromycin and Clindamycin Resistance and Telithromycin Susceptibility in Streptococcus agalactiae. Antimicrob. Agents Chemother. 47: 1112-1114 [Abstract] [Full Text]